Inhibrx Biosciences, Inc. (INBX)
NASDAQ:INBX
Want to see INBX full AI Analyst Report?
Top Page
Inhibrx Biosciences Inc
(NASDAQ:INBX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$92.00
▲(7.83% Upside)
Action:Reiterated
Date:06/16/26
The score is held down primarily by very weak financial performance (large ongoing losses, heavy cash burn, and negative equity). Technicals also lean bearish with the stock below key moving averages and negative MACD. Offsetting these risks, corporate events are strong, highlighted by FDA BLA acceptance and positive clinical readouts that improve the company’s near-term catalyst profile.
Positive Factors
Regulatory milestone: BLA accepted for ozekibart
FDA acceptance starts a formal review clock and signals the submission met filing standards. This materially reduces near-to-medium term regulatory uncertainty for ozekibart and creates a clear, durable pathway to first commercial product potential and partner/license negotiation leverage.
Negative Factors
Substantial cash burn and negative free cash flow
Persistent negative operating and free cash flow of roughly $132M TTM creates a structural dependence on external financing to fund development and potential launch activities. This raises dilution risk, limits strategic flexibility, and may constrain investment pacing absent financing alternatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory milestone: BLA accepted for ozekibart
FDA acceptance starts a formal review clock and signals the submission met filing standards. This materially reduces near-to-medium term regulatory uncertainty for ozekibart and creates a clear, durable pathway to first commercial product potential and partner/license negotiation leverage.
Read all positive factors
Inhibrx Biosciences Inc (INBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.37B
Dividend YieldN/A
Average Volume (3M)434.66K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth550.00%
EPS Growth-107.04%
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.39
Shares Outstanding14,671,186
10 Day Avg. Volume333,594
30 Day Avg. Volume434,660
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue943.29
Enterprise Value/Gross Profit-2.65K
Enterprise Value/Ebitda-10.47
Forecast
1Y Price Target
$277.50Price Target Upside225.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.83
Revenue Forecast (FY)N/A
Inhibrx Biosciences Inc Business Overview & Revenue Model
Company Description
Inhibrx Biosciences, Inc. is a biopharmaceutical company currently in its clinical development phase, focused on creating and advancing biological treatments for patients afflicted with severe, life-threatening medical conditions. Its pipeline fea...
How the Company Makes Money
null...
Inhibrx Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
25
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.30M | 1.30M | 200.00K | 1.80M | 2.19M | 7.13M |
| Gross Profit | -463.00K | -1.18M | -2.08M | 609.00K | -107.99M | 4.44M |
| EBITDA | -117.09M | -132.54M | 1.70B | -206.69M | -125.82M | -75.37M |
| Net Income | -130.19M | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M |
Balance Sheet | ||||||
| Total Assets | 183.97M | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M |
| Cash, Cash Equivalents and Short-Term Investments | 161.66M | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M |
| Total Debt | 5.90M | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M |
| Total Liabilities | 205.00M | 138.49M | 47.18M | 264.39M | 232.82M | 98.07M |
| Stockholders Equity | -21.04M | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M |
Cash Flow | ||||||
| Free Cash Flow | -131.94M | -129.82M | -197.01M | -197.90M | -115.99M | -81.19M |
| Operating Cash Flow | -131.93M | -129.79M | -194.41M | -193.31M | -115.30M | -80.32M |
| Investing Cash Flow | -7.00K | -28.00K | -2.60M | -4.59M | -686.00K | -809.00K |
| Financing Cash Flow | 77.07M | 101.45M | 71.68M | 201.96M | 258.55M | 83.77M |
Inhibrx Biosciences Inc Technical Analysis
Neutral
85.32
Price Trends
104.53
Negative
88.80
Positive
75.06
Positive
Market Momentum
-3.79
Negative
43.65
Neutral
66.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Neutral. The current price of 85.32 is below the 20-day moving average (MA) of 96.17, below the 50-day MA of 104.53, and above the 200-day MA of 75.06, indicating a neutral trend. The MACD of -3.79 indicates Negative momentum. The RSI at 43.65 is Neutral, neither overbought nor oversold. The STOCH value of 66.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INBX.
Inhibrx Biosciences Inc Risk Analysis
Inhibrx Biosciences Inc disclosed 88 risk factors in its most recent earnings report. Inhibrx Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibrx Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.55B | -9.23 | -40.99% | ― | -73.07% | -2335.85% | |
55 Neutral | $608.88M | -9.52 | -60.42% | ― | ― | 26.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $642.22M | -8.84 | -36.61% | ― | -75.91% | -173.33% | |
49 Neutral | $249.25M | -1.87 | -2781.56% | ― | 289.94% | 16.60% | |
46 Neutral | $1.37B | -11.14 | -563.89% | ― | 550.00% | -107.04% | |
46 Neutral | $467.51M | -3.17 | -49.88% | ― | -57.99% | -37.06% |
* Healthcare Sector Average
INBX
Inhibrx Biosciences Inc
93.05
78.49
539.08%
PRTA
Prothena
8.93
2.87
47.36%
CTMX
CytomX Therapeutics
2.95
0.79
36.57%
HUMA
Humacyte
0.92
-1.29
-58.19%
GLUE
Monte Rosa Therapeutics
18.31
13.67
294.61%
CADL
Candel Therapeutics
8.31
3.64
77.94%
Inhibrx Biosciences Inc Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Inhibrx Biosciences BLA Accepted for Ozekibart Chondrosarcoma Therapy
Positive
Jun 15, 2026
On June 15, 2026, Inhibrx Biosciences Inc. announced that the U.S. Food and Drug Administration accepted for filing its Biologics License Application for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondros...
Executive/Board ChangesShareholder Meetings
Inhibrx Biosciences Holds 2026 Virtual Annual Shareholder Meeting
Neutral
Jun 3, 2026
Inhibrx Biosciences Inc. held its 2026 Annual Meeting of Stockholders on June 3, 2026, in a virtual format, with approximately 79% of the 14.6 million eligible common shares present or represented by proxy, underscoring strong shareholder particip...
Business Operations and StrategyProduct-Related Announcements
Inhibrx Biosciences Reports Positive Interim Phase 2 Results
Positive
May 11, 2026
On May 11, 2026, Inhibrx Biosciences reported positive interim Phase 2 data from its HexAgon trial evaluating INBRX-106, a hexavalent OX40 agonist, plus pembrolizumab versus pembrolizumab alone in first-line, PD-L1 high metastatic or unresectable ...
Business Operations and StrategyProduct-Related Announcements
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
Positive
Apr 21, 2026
On April 21, 2026, Inhibrx Biosciences reported updated interim results from a Phase 1/2 trial of its DR5 agonist antibody ozekibart (INBRX-109) combined with FOLFIRI in locally advanced or metastatic, unresectable colorectal cancer. As of the Apr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.